Rivaroxaban

Rivaroxaban (BAY 59-7939) is a highly potent, selective and direct Factor Xa (FXa) inhibitor, achieving a strong gain in anti-FXa potency (IC50 0.7 nM; Ki 0.4 nM) [1][2].

Product Specifications

CAS Number

[366789-02-8]

Product Name Alternative

BAY 59-7939

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Factor Xa

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Cardiovascular Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/Rivaroxaban.html

Purity

99.93

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C(N(C1=CC=C(N2C(COCC2)=O)C=C1)C3)O[C@H]3CNC(C4=CC=C(S4)Cl)=O

Molecular Formula

C19H18ClN3O5S

Molecular Weight

435.88

Precautions

H302, H315, H319, H335

References & Citations

[1]Roehrig S, et al. Discovery of the novel antithrombotic agent 5-chloro-N- ({ (5S) -2-oxo-3- [4- (3-oxomorpholin-4-yl) phenyl]-1,3-oxazolidin-5-yl}methyl) thiophene- 2-carboxamide (BAY 59-7939) : an oral, direct factor Xa inhibitor. J Med Chem. 2005 Sep 22;48 (19) |[2]Perzborn E, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor. J Thromb Haemost. 2005 Mar;3 (3) :514-21.